

UBM Medica Psychiatric Times

Psychiatric Times.
CLINICAL Q&A

Medical Marijuana: Regulations Surrounding Its Use

By Marie-Josée Lynch, MD, and Tony P. George, MD | September 14, 2012


Dr Lynch is a PGY-4 Resident in Psychiatry at the University of Toronto. Dr George is Professor and Chair in Addiction Psychiatry at the University of Toronto, and Clinical Director of the Schizophrenia Program at the Centre for Addiction and Mental Health in Toronto. Dr George reports that in the past 2 years, he has received grant support from Pfizer; has been a speaker for Astra Zeneca, Eli Lilly, and Pfizer; and served as a consultant to Abbott, Novartis, Pfizer, and Sepracor. Dr Lynch has no conflicts of interest concerning the subject matter of this article.

The use of [cannabis](#) as a viable medical treatment for people with cancer, eating disorders, chronic pain, and a number of other illnesses, remains an area of concern for everyone involved. Here, we ask the experts, Marie-Josée Lynch, MD, and Tony P. George, MD, about the use of cannabis and regulations surrounding its use.

Question: Which of the following statement(s) about medical marijuana is/are true?

- A. California's Proposition 215, also known as the Compassionate Use Act, was the first law in the US that stipulated that individuals could legally possess and use marijuana if recommended by their physicians.
- B. The majority of medical marijuana patient identification cards are granted for the treatment of cancer and AIDS-related symptoms.
- C. The potency of medical marijuana tends to be fairly uniform among dispensaries.
- D. Evidence from case-control studies suggests that long-term use of medical marijuana confers a greater risk of respiratory, cardiovascular, and psychiatric illness.

For the answer and discussion, [please click here](#).



Answer: A.

California's Proposition 215, also known as the Compassionate Use Act, was the first law in the US that stipulated that individuals could legally possess and use marijuana if recommended by their physicians.

Discussion

Cannabis (*Cannabis sativa*) was used for medicinal and religious purposes long before it gained its current status as the most commonly used recreational illicit substance

in the US.¹ In recent years, there has been rising interest in its potential therapeutic value, with resulting pressures to legalize its use. The medical and legal communities have simultaneously found themselves at an important decision point in the history of this well-known substance.

In 1996, California became the first state to pass a law allowing individuals to possess small quantities of marijuana for their own medical use. This law, known as Proposition 215 or the Compassionate Use Act, stipulated that a physician may “recommend” the use of marijuana for the treatment of “cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness for which marijuana provides relief.”² A total of 15 states have since followed suit, although the specific medical diagnoses for which marijuana may be “recommended” varies broadly amongst them.³

Although Proposition 215 implies that marijuana be used as a medical treatment, regulations surrounding its use are much less rigorous than the FDA monitoring of regular prescription medications. Most state laws do not stipulate the means by which individuals can access the substance, which leads to significant heterogeneity of the marijuana used by patients. Some procure their marijuana through dispensaries (which themselves can vary greatly in terms of their crops), while others grow their own supplies. These disparate means of accessing marijuana complicate the evaluation of the quality, purity, and potency of cannabis. This results in physicians recommending a substance for which the dose cannot be standardized and where quality control becomes an impossible task. It is also important to note that medical marijuana is the only therapeutic agent approved to be delivered by means of smoking, and thus does not fall under the regulation of the FDA.⁴

Another area of ambiguity involves the medical diagnoses for which cannabis is recommended as a treatment. Although initially intended to treat cancer and AIDS-related symptoms such as nausea and pain, these indications comprise only a small fraction of the reasons cited for the prescription of medical marijuana patient identification cards. In fact, musculoskeletal pain (30.6%), insomnia (15.5%), and anxiety (13%) were the most common cited reasons.⁵ Yet another conundrum faced by physicians is their duty to educate their patients on the medical use of marijuana. The process of informed consent requires that a discussion about the benefits, risks, and alternatives for any proposed treatment must occur in order for the patient to make an informed decision. Those recommending medical marijuana must comply with these standards. However, there are no studies investigating the long-term effects of smoked medical marijuana use.⁶ Coupled with the paucity of well-designed studies investigating the therapeutic benefits of marijuana, it becomes impossible for physicians to educate their patients about the pros and cons of medical marijuana use.

Marijuana’s current status as a Schedule I Substance by the federal government further impedes research efforts to resolve these issues, since investigators who wish to study marijuana’s potential therapeutic benefits must face strict and often cumbersome regulations and restrictions imposed by the Drug Enforcement Agency.⁷ Along with other political considerations, this poses an important obstacle for investigators who wish to expand our understanding of the potential uses and risks of cannabis. The important question of whether the benefits of medical marijuana outweigh its risks thus remains unanswered.

References:

1. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*.

2009;374:1383-1391.

2. Rojas LM. Californias Compassionate Use Act and the federal governments medical marijuana policy: can California physicians recommend marijuana to their patients without subjecting themselves to sanctions? *McGeorge Law Rev.* 1999;30:1373-1425.
3. Hoffman DE, Weber E. Medical marijuana and the law. *N Engl J Med.* 2010;362:1453-1457.
4. Kleber HD, DuPont RL. Physicians and medical marijuana (commentary). *Am J Psychiatry.* 2012;169:564-568.
5. Reinerman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. *J Psychoactive Drugs.* 2011;43:128-135.
6. Degenhardt L, Hall WD. The adverse effects of cannabinoids: implications for use of medical marijuana. *CMAJ.* 2008;178:1685-1686.
7. Cohen PJ. Medical marijuana 2010: its time to fix the regulatory vacuum. *J Law Med Ethics* 2010;38:654-666.